Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study

NCT05874674 is registered in ClinicalTrials.gov with Wonju Severance Christian Hospital as lead sponsor.

NCT NCT05874674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05874674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study
Lead sponsor
Wonju Severance Christian Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
December 1, 2023
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bleeding, dialysis; complications